Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1289-1299

  Ludovini, V ^a   Bianconi, F ^b   Pistola, L ^a   Minotti, V ^a   Chiari, R ^a   Colella, R ^b   Bellezza, G ^b   Tofanetti, F R ^a   Siggillino, A ^a   Baldelli, E ^a   Flacco, A ^a   Giuffrida, D ^c   Sidoni, A ^b   Crino L ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Istituto Oncologico Del Mediterraneo   (Italy)

Author keywords

EGFR; KRAS; MET mutations; NSCLC; PI3KCA; Response to TKIs

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; NAVELBINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; SCATTER FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MET PROTEIN, HUMAN; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER TISSUE; COHORT ANALYSIS; DNA SEQUENCE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT SELECTION; PHARMACOGENETICS; PHOSPHATIDYLINOSITOL 3 KINASE GENE; POINT MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCATTER FACTOR RECEPTOR GENE; SIGNAL TRANSDUCTION; TIME TO PROGRESSION; TREATMENT RESPONSE; DRUG RESISTANCE; FOLLOW UP; GENETICS; LUNG TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PATIENT SELECTION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862294110     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1829-7     Document Type: Article

References (31)

1. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
2. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291 (Pubitemid 35266288)
3. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799 (Pubitemid 46606324)
4. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol 21:2237-2246 (Erratum, J Clin Oncol 2004;22:4811) (Pubitemid 46621858)
5. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158 (Pubitemid 37432975)
6. Perez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247 (Pubitemid 41103678)
7. Miller VA, Kris MG, Shah N et al (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109 (Pubitemid 41095044)
8. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181
9. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M et al (2005) Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2:e313
10. Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoSMed 2:e17
11. Tam IY, Chung LP, Suen WS et al (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12:1647-1653
12. Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909
13. Taron M, Ichinose Y, Rosell R et al (2005) Activating mutations in the tyrosine kinase domain in the EGFR are associated with improved survival in Gefitinib-treated chemorefractory lung adenocarcinomas. Clin Can Res 11:5878-5885 (Pubitemid 41170316)
14. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of NSCLC to Gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
15. Paez JG, Jänne PA, Lee JC et al (1999) EGFR mutations in lung with resected stage I and II non-small-cell lung cancer. J Clin Oncol 17:668-675
16. Cortes-Funes H, Gomez C, Rosell R et al (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinibtreated non-small-cell lung cancer patients. Ann Oncol 16:1081-1086 (Pubitemid 41418309)
17. Han SW, Kim TY, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501
18. Mitsudomi T, Kosaka T, Endoh H et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520 (Pubitemid 47050841)
19. Takano T, Ohe Y, Sakamoto H et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-smallcell lung cancer. J Clin Oncol 23:6829-6837
20. Kang S, Bader AG, Vogt PK et al (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102:802-807 (Pubitemid 40282746)
21. Ludovini V, Bianconi F, Pistola L et al (2011) Phosphoinositide- 3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced nonsmall cell lung cancer. J Thorac Oncol 6(3):1-9
22. Lim EH, Zhang SL, Li JL et al (2009) Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, P53, MET mutations in advanced stage NSCLC. JTO 4(1):12-21
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655 (Pubitemid 13149996)
25. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (2004) World health organization classification of tumours. Pathology and genetics of tumours of lung, pleura, thymus and heart. IARC Press, Lyon
26. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042 (Pubitemid 46631407)
27. Sasaki H, Shimizu S, Endo K et al (2006) EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118:180-184 (Pubitemid 41681596)
28. Mok T, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Eng J Med 361(10):947-957
29. Inoue A, Kobayashi K, Usui K et al (2009) North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27(9):1394-1400
30. Lee JS, Park K, Kim SW et al (2009) A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 4(suppl):S283
31. Kim HJ, Lee KY, Kim YC et al (2011) Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer. 17 Sep 2011 [Epub ahead of print]